Evidence map›Paper›PMID 19675456›Full record

ArticleBehavioural pharmacology2009

Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Scott A Heldt, Michael Davis, Emiliangelo Ratti, Mauro Corsi, David Trist, Kerry J Ressler

Open access · greenAbstract read
In one paragraph

Article in Behavioural pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2011
    Trial
  3. Endocannabinoid signaling in stress, nausea, and vomiting.Neurogastroenterology and motility · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Scott A HeldtDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. sheldt@emory.edu
Michael Davis
Emiliangelo Ratti
Mauro Corsi
David Trist
Kerry J Ressler
Emory University · USGlaxoSmithKline (Italy) · IT

Funding

Projevt 5: Effects of the CRF1 receptor antagonist in patients w/PTSD: a plcebocoU19MH069056 · NIMH · EMORY UNIVERSITY · PI DAVIS, MICHAEL E · 2003 to 2013
$15.4M
ANATOMY AND PHARMACOLOGY OF FEAR-POTENTIATED STARTLER37MH047840 · NIMH · YALE UNIVERSITY · PI DAVIS, MICHAEL NMN · 1991 to 2010
$3.6M
Molecular Regulation of GABA(A) Receptor Function in AmygdalaR01DA019624 · NIDA · EMORY UNIVERSITY · PI RESSLER, KERRY J. · 2006 to 2010
$1.8M
DOPAMINERGIC MODULATION OF THE STARTLE REFLEXR01MH059906 · NIMH · EMORY UNIVERSITY · PI DAVIS, MICHAEL NMN · 2000 to 2004
$786k
ROLE OF THE BED NUCLEUS OF THE STRIA TERMINALIS AND FEARR01MH057250 · NIMH · YALE UNIVERSITY · PI DAVIS, MICHAEL · 1997 to 2001
$724k
Anatomy and Pharmacology of Fear-Potentiated StartleR01MH047840 · NIMH · EMORY UNIVERSITY · PI WALKER, DAVID · 2011 to 2011
$418k
The Role of Amygdala GABAergic Transmission in Fear and AnxietyR21MH086727 · NIMH · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI HELDT, SCOTT A · 2010 to 2011
$402k
GABA Receptors in the Acquisition and Extinction of FearF32MH073389 · NIMH · EMORY UNIVERSITY · PI HELDT, SCOTT A · 2004 to 2006
$149k
NIDA NIH HHS DA-019624NIDA NIH HHS R01 DA019624NIMH NIH HHS F32 MH073389NIMH NIH HHS F32 MH073389-01NIMH NIH HHS MH047840NIMH NIH HHS MH069056NIMH NIH HHS MH57250NIMH NIH HHS MH59906NIMH NIH HHS R01 MH047840NIMH NIH HHS R01 MH057250NIMH NIH HHS R01 MH059906NIMH NIH HHS R21 MH086727NIMH NIH HHS R37 MH047840NIMH NIH HHS U19 MH069056
6 · The paper itself

Abstract

Gerbils show a neurokinin (NK)1 receptor pharmacological profile, which is similar to that observed in humans, and thus have become a commonly used species to test efficacy of NK1 receptor antagonists. The aim of this study was to determine whether systemic administration of the NK1 receptor antagonist GR-205171 produced anxiolytic-like effects in the elevated plus maze and in a novel contextual conditioned fear test using fear-potentiated startle (FPS). On the elevated plus maze, treatment with GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing produced anxiolytic-like effects in an increasing dose-response manner as measured by the percentage of open arm time and percentage of open arm entries. For contextual fear conditioning, gerbils were given 10 unsignaled footshocks (0.6 mA) at a 2-min variable interstimulus interval in a distinctive training context. Twenty-four hours after training, gerbils received treatment of GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing in which startle was elicited in the same context in which they were trained. Contextual FPS was defined as an increase in startle over pretraining baseline values. All drug dose levels (0.3, 1.0, and 5.0 mg/kg) significantly attenuated contextual FPS when compared with the vehicle control group. A control group, which received testing in a different context, showed little FPS. These findings support other evidence for anxiolytic activity of NK1 receptor antagonists and provide a novel conditioned fear test that may be an appropriate procedure to test other NK1 antagonists for preclinical anxiolytic activity in gerbils.

Indexed as

Neurokinin-1 Receptor AntagonistsAnimalsAnti-Anxiety AgentsAnxietyDose-Response Relationship, DrugFearGerbillinaeMaleMaze LearningModels, AnimalPiperidinesReflex, StartleTetrazolesAnti-Anxiety AgentsNeurokinin-1 Receptor AntagonistsPiperidinesTetrazolesvofopitant

Identifiers

PMID19675456
PMCPMC2946835
OpenAlexW2049305164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.